The Management of Lower Urinary Tract Obstruction in Patients with Advanced Prostate Cancer

• Yervand S. Harutyunyan

  Medical Center Named After Vladimir Avagyan. Moskovyan str. 15, Yerevan, Armenia

• Haykaz Y. Antonyan

  Medical Center Named After Vladimir Avagyan. Moskovyan str. 15, Yerevan, Armenia

• Tigran Y. Antonyan

  Medical Center Named After Vladimir Avagyan. Moskovyan str. 15, Yerevan, Armenia

• Lernik Y. Hambardzumyan

  Medical Center Named After Vladimir Avagyan. Moskovyan str. 15, Yerevan, Armenia

• Sargis S. Gevorgyan

  Medical Center Named After Vladimir Avagyan. Moskovyan str. 15, Yerevan, Armenia

 Objectives: To determine the optimal time to wait for urination ability restoration after urethral catheterization and anti - androgen treatment, in cases of acute urinary retention and advanced prostate cancer.

Methods: We enrolled 26 patients with histologically confirmed prostate cancer after transrectal ultrasound guided biopsy of the prostate and CT or MRI proven advanced stages (T3-T4). We evaluated the dynamic changes of the following factors; IPSS, QoL, Vmax, residual urine, serum concentration of PSA at the following periods; before hormonal treatment, 1, 3 and 6 months after hormonal treatment.

Results: How long we have to wait after urethral catheter insertion and hormonal treatment for voiding ability restoration?

Our data analyses revealed the answer to this question. The dynamic changes of all the parameters (IPSS, QoL, Vmax, PSA) we studied disclosed interesting regularity. The consequent comparative analyses of parameters showed statistically significant changes only 1 month after anti - androgen treatment. These changes indicate that the prostate cancerous process is significantly suppressed within 1 month after hormonal treatment and there is no point to wait more than 1 month.

Conclusion: Analyzing our data we obtained versatile evidence, that in advanced prostate cancer and acute urinary retention cases the optimal time to wait for sufficient voiding is 1 month period after permanent catheter insertion and anti - androgen treatment.

Matveev VB. Screening of prostate cancer. Is it needed? Russian experience. Arch Ital Urol Androl 2006; 78(4): 149-51.

Varenhorst E, Alund G. Urethral obstruction secondary to carcinoma of prostate: response to endocrine treatment. Urology 1985; 25: 345-56. http://dx.doi.org/10.1016/0090-4295(85)90485-6

Sehgal A, Mandhani A, Gupta N, Dubey D, Srivastava A, Kapoor R, Kumar A. Can the need for palliative transurethral prostatic resection in patients with advanced carcinoma of the prostate be predicted? J Endourol 2005; 19(5): 546-9. http://dx.doi.org/10.1089/end.2005.19.546

Mommsen S, Petersen L. Transurethral catheter removal after bilateral orchiectomy for prostatic carcinoma associated with acute urinary retention. Scand J Urol Nephrol 1994; 28(4): 401-4. http://dx.doi.org/10.3109/00365599409180520

Gleave ME, Goldenberg SL, Jones EC, et al. Optimal duration of neoadjuvant androgen withdrawal therapy before radical prostatectomy in clinically confined prostate cancer. Sem Urol Oncol 1996; 14(suppl 2): 39-47.

Crawford ED, Eisenburger MA, McLeod DG, et al. A controlled trial of leuprolide with and without flutamide in prostatic carcinoma. N Engl J Med 1989; 321: 419-24. http://dx.doi.org/10.1056/NEJM198908173210702

Chute R, Willetts AT, Gens JP. Experiences in the treatment of carcinoma of the prostate with stilbestrol and with castration by the technique of intra-capsular orchidectomy. J Urol 1942; 48: 682.

Vaillancourt L, Tetu B, Fradet Y, et al. Effect of neoadjuvant endocrine therapy (combined androgen blockage) on normal prostate and prostatic carcinoma. J Surg Pathol 1996; 20: 86-93. http://dx.doi.org/10.1097/00000478-199601000-00010

Fleischmann JD, Catalona WJ. Endocrine therapy for bladder outlet obstruction from carcinoma of the prostate. J Urol 1985; 134: 498-500.

Thomas DJ, Balaji VJ, Coptcoat MJ, Abercrombie GF. Acute urinary retention secondary to carcinoma of the prostate. Is initial channel TURP beneficial? J Roy Soc Med 1992; 85(3): 318-19.

Varenhorst E, Alund G. Urethral obstruction secondary to carcinoma of prostate: response to endocrine treatment. Urology 1985; 25: 345-56. http://dx.doi.org/10.1016/0090-4295(85)90485-6

Carpentier PJ, Schroder FH. Transrectal ultrasonography in the followup of prostatic carcinoma patients: a new prognostic parameter? J Urol 1984; 131: 903-5.

• PDF